公开(公告)号：US20210023120A1

公开(公告)日：2021-01-28

申请号：US17064505

申请日：2020-10-06

Applicant: The Board of Regents of the University of Texas System

Inventor： Daniel J. Siegwart ,  Philip J. Thomas ,  Arthur E. Johnson ,  Michael J. Torres ,  Jason B. Miller

IPC: A61K31/7105 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/20 ,  A61K47/34

Abstract: In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.

公开(公告)号：US20170354672A1

公开(公告)日：2017-12-14

申请号：US15597063

申请日：2017-05-16

Applicant: The Board of Regents of the University of Texas System

Inventor： Daniel J. Siegwart ,  Philip J. Thomas ,  Arthur E. Johnson ,  Michael J. Torres ,  Jason B. Miller

IPC: A61K31/7105 ,  A61K47/18 ,  A61K47/20 ,  A61K47/34

CPC classification number: A61K31/7105 ,  A61K9/127 ,  A61K9/5123 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/20 ,  A61K47/34

Abstract: In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.